Send PM
Followers 2
Posts 230
Boards Moderated 0
Alias Born 02/16/2021

Re: None

Friday, 11/04/2022 10:39:25 PM

Friday, November 04, 2022 10:39:25 PM

Post# of 4884
New 8K out today. Not sure what in means going forward but I would not think it is.

Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

On October 28, 2022, the Board of Directors of Instadose Pharma Corp was notified by our independent Auditor BF Borgers CPA PC (the “Auditor”) that Instadose is required to disclose that the February 28, 2022, financial statements were not reviewed by the Auditor.

On November 2, 2022, the Company’s Board of Directors met and then acting under authority delegated to it, approved the disclosure described below in this Form 8-K.

Instadose is advising that the financial statements as at February 28, 2022 and the associated 10-Q were not reviewed by the Auditor. Management of Instadose provided disclosure that the financial statements and 10-Q were unaudited, however, further disclosure is now being provided that the February 28, 2022, financial statements and 10-Q were also not reviewed by the Auditor.

Instadose has requested that the Auditor furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statement. A copy of the letter from the Auditor Firm is attached hereto as Exhibit 16.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description
16.1

Letter from BF Borgers CPA PC
104

Cover Page Interactive Data File (embedded within the Inline XBRL Document)


2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Instadose Pharma Corp.




/s/ Alex Wylie
By:
Alex Wylie, Interim CEO
November 4, 2022


3

EXHIBIT 16.1


5400 W Cedar Ave
Lakewood, CO 80226
Telephone: 303.953.1454
Fax: 303.945.7991

November 3, 2022

United States Securities and Exchange Commission
Office of the Chief Accountant
100 F Street, N.E.
Washington, D.C. 20549

Re: Instadose Pharma Corp

Ladies and Gentleman:

We have read the statements under item 4.02 in the Form 8-K dated November 3, 2022, of Instadose Pharma Corp (the “Company”) to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm.

Sincerely,